Development of the fluorescence polarization-based competition assay for the E3 ligase GID4
Bioorganic & Medicinal Chemistry Letters · 2026-04 · 133 · 130528
DOI: 10.1016/j.bmcl.2025.130528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-04. Verfasst von Meiling Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Ph…. Hauptthemen laut MEDLINE: Fluorescence Polarization, Ubiquitin-Protein Ligases, Fluorescent Dyes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Tianjin Municipal Education Commission.
Abstract (Originalsprache)
The proteolysis-targeting chimera (PROTAC) technology utilizes heterobifunctional molecules to induce targeted protein degradation through the ubiquitin-proteasome system. Structurally, PROTAC molecules consist of a target protein ligand and an E3 ligase ligand covalently linked by a suitable linker arm, forming the target protein-PROTAC-E3 ligase stable ternary complex and bringing the target protein in proximity to the E3 ligase for ubiquitination and subsequent proteasomal degradation. However, only a few E3 ligases have been used to generate effective PROTACs with limited small molecule E3 ligase ligands. Therefore, there is an urgent need to discover novel E3 ligase ligands to expand the toolbox for PROTACs. Unlike traditional E3 ligases such as CRBN and VHL, GID4 E3 ligase recognizes substrates bearing N-terminal proline or other small residues through the Pro/N-degron pathway, and has already been successfully leveraged in PROTAC technology. Here, we reported the development of a fluorescent probe YG11, with a Kd value of 8.1 ± 0.7 nM for GID4. With this probe, we established a robust fluorescence polarization (FP)-based competition assay for evaluation of GID4 ligands. The assay exhibited a high signal-to-noise ratio of over 20, 2.5 % DMSO tolerance, and a Z'-factor of 0.84, confirming its suitability and robustness for high-throughput screening. Thus, by enabling rapid identification of GID4 ligands, this FP competition assay promises to substantially advance PROTAC development initiatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
- Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Biochemistry and Molecular Bio…
- Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. Electronic…
Förderung
- Tianjin Municipal Education Commission
Zitieren
APA
Zhang, M., Xiao, S., Yan, K., Sun, J., Xi, C., Qin, Y., Dong, C., & Chen, D. (2026). Development of the fluorescence polarization-based competition assay for the E3 ligase GID4. Bioorganic & Medicinal Chemistry Letters, 133, 130528. https://doi.org/10.1016/j.bmcl.2025.130528
Vancouver
Zhang M, Xiao S, Yan K, Sun J, Xi C, Qin Y, et al. Development of the fluorescence polarization-based competition assay for the E3 ligase GID4. Bioorganic & Medicinal Chemistry Letters. 2026;133:130528. doi:10.1016/j.bmcl.2025.130528
BibTeX
@article{Zhang2026,
author = {Zhang, Meiling and Xiao, Shijia and Yan, Kexin and Sun, Jiyue and Xi, Chen and Qin, Yuhong and Dong, Cheng and Chen, Dongxing},
title = {Development of the fluorescence polarization-based competition assay for the E3 ligase GID4},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {133},
pages = {130528},
doi = {10.1016/j.bmcl.2025.130528}
}
EUVIMED